抗血栓药物的临床应用研究进展
|
摘要
非正常凝血可导致血栓形成、动脉粥样硬化等疾病,抗血栓药物能有效预防血栓的形成。该文依据抗血栓药物的作用机制和临床研究,对抗血小板聚集、抗凝血和溶栓类抗血栓药物进行综述。
Abnormal blood coagulation may cause some diseases,such as thrombosis,atherosclerosis. Antithrombotic drugs can effectively prevent the formation of thrombus. According to mechanism of action and clinical research of antithrombotic agents,three types of antithrombotic drugs are summarized.
Abnormal blood coagulation may cause some diseases,such as thrombosis,atherosclerosis. Antithrombotic drugs can effectively prevent the formation of thrombus. According to mechanism of action and clinical research of antithrombotic agents,three types of antithrombotic drugs are summarized.
引文
[1]李勇.心血管疾病急诊分析及临床治疗方法探讨[J].中国社区医师,2016,32(2):107,109.
[2]KEARON C,AKL EA,COMEROTA AJ,et al.Antithrombotic and thrombolytic therapy for valvular disease:Antithrombotic Therapy and Prevention of Thrombosis,9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J].J Thromb Thrombolysis,1999,141(2):1513-1514.
[3]蒋如男,姚学军,乔兰芳,等.体外血栓检测在急性心脑血管病预防中的应用[J].河北医药,1991,13(3):152-153.
[4]程鹏飞,魏增泉.抗血小板药物研究进展[J].世界中西医结合杂志,2012,7(7):639-642.
[5]吴小平,刘放.抗血小板聚集药物研究进展[J].西北药学杂志,2009,24(4):327-330.
[6]TORPHY TJ,UNDEM BJ.Phosphodiesterase inhibitors:new opportunities for the treatment of asthma[J].Thorax,1991,46(7):512-523.
[7]GIACHINI FR,LIMA VV,CARNEIRO FS,et al.Decreased c GMP level contributes to increased contraction in arteries from hypertensive rats:role of phosphodiesterase1[J].Hypertension,2011,57(3):655-663.
[8]陈昌亮,黄爽.磷酸二酯酶及其抑制剂的研究进展[J].中国药理学通报,2014,30(2):283-286.
[9]杨颖,蒋金法.新型抗血小板药物研究进展[J].外科研究与新技术,2014,3(4):263-266.
[10]崔炜,耿雪.新型抗栓药的临床应用[J].中国心血管杂志,2015,20(5):328-333.
[11]赵磊.双嘧达莫联合丹参酮ⅡA磺酸钠对心绞痛患者血流速度的影响[J].中国老年学,2012,32(20):4367-4368.
[12]DAVIDAI G,COTTON D,GORELICK P,et al.Dipyridamole-induced headache and lower recurrence risk in secondary prevention of ischaemicstroke:a post hoc analysis[J].Eur J Neurol,2014,21(10):1311-1317.
[13]徐伟,曹蘅.Ⅱb/Ⅲa受体抑制剂治疗急性冠脉综合征的最新研究进展[J].心脏杂志,2014,26(2):233-235.
[14]AHN SG,LEE SH,JI HL,et al.Efficacy of combination treatment with intracoronaryabciximab and aspirationthrombectomy on myocardialperfusion in patients with ST-segmentelevation myocardial infarction undergoing primary coronary stenting[J].Yonsei Med J,2014,55(3):606-616.
[15]陶军,刘磊,杨惜泉,等.阿昔单抗降低急性心肌梗死直接PTCA术缺血危险性的观察[J].中华老年心脑血管病杂志,2001,3(6):390-392.
[16]罗亚玮,陈方,潘昱,等.血小板糖蛋白Ⅱb/Ⅲa受体拮抗药替罗非班的抗血小板以外作用[J].中国药房,2015,26(2):278-281.
[17]CAVARRETTA E,CHIARIELLO GA,CONDORELLI G.Platelets,endothelium,and circulating microRNA-126 as a prognostic biomarker in cardiovascular diseases:per aspirin ad astra[J].Eur Heart J,2013,34(44):3400-3402.
[18]梁峰,胡大一,沈珠军,等.小剂量阿司匹林在心脑血管事件一级预防中的研究进展[J].中国医院用药评价与分析,2014,14(11):1044-1048.
[19]许璨.冠心病心绞痛患者经皮冠状动脉介入围手术期对阿司匹林和氯吡格雷抗血小板效应分析[J].心血管病防治知识,2015(8):67-68.
[20]MOUSA SA,JESKE WP,FAREED J.Antiplatelettherapyprasugrel:anovelplatelet ADP P2Y12 receptorantagonist[J].Clin Appl Thromb Hemost,2010,16(2):170-176.
[21]ELLIS KJ,STOUFFER GA,MCLEOD HL,et al.Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition:USFDA recommendations[J].Pharmacogenomics,2009,10(11):1799-1817.
[22]叶金朝.噻氯匹定的药理及临床应用[J].新药与临床,1990,9(5):291-292.
[23]李江,刘文娴,赵一楠,等.替格瑞洛在治疗氯吡格雷抵抗患者时血小板聚集率分析[J].中国全科医学,2014,17(19):2231-2234.
[24]何芸,王淑香,赵强,等.替格瑞洛与氯吡格雷用于急性冠状动脉综合征疗效及安全性比较的Meta分析[J].白求恩医学杂志,2015,13(4):354-356.
[25]张菁蕾.肝素抗凝血血浆用于急诊生化检验的效果分析[J].实用心脑肺血管病杂志,2013,21(11):104-105.
[26]王小东,刘学波.急性冠脉综合征新型抗凝药物研究进展[J].国际心血管病杂志,2015,42(1):6-9.
[27]高昉,储慧民.达比加群酯在心房颤动抗凝治疗方面的研究进展[J].临床荟萃,2015,30(11):1316-1320.
[28]姚璐,张薇,田国祥,等.达比加群酯应用于高龄老年非瓣膜性心房纤颤患者中的安全性评价[J].中国循证心血管医学杂志,2016,8(5):547-549.
[29]徐梅,韩强,杜金凤.一例口服华法林引起出血的病例分析[J].北方药学,2014,11(11):33-35.
[30]张清.新型Xa因子抑制剂——依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,37(2):151-155.
[31]王兵,刘颖,刘登科,等.直接Xa因子抑制剂贝曲沙班[J].现代药物与临床,2015,30(2):217-221.
[32]杨平.利伐沙班与华法林对非瓣膜性房颤预防血栓栓塞128例疗效观察[J].中国煤炭工业医学杂志,2015,18(1):14-16.
[33]苟冶然,龙小滨,白磊,等.RGD-重组葡激酶-人α微球蛋白融合蛋白原核表达、纯化及鉴定[J].基础医学与临床,2015,35(3):329-335.
[34]李淑娟,谢秀峰,陈凤英.重组人组织型纤溶酶原激酶衍生物静脉溶栓治疗急性心肌梗死的疗效观察[J].中西医结合心脑血管病杂志,2014,12(8):952-954.
[2]KEARON C,AKL EA,COMEROTA AJ,et al.Antithrombotic and thrombolytic therapy for valvular disease:Antithrombotic Therapy and Prevention of Thrombosis,9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J].J Thromb Thrombolysis,1999,141(2):1513-1514.
[3]蒋如男,姚学军,乔兰芳,等.体外血栓检测在急性心脑血管病预防中的应用[J].河北医药,1991,13(3):152-153.
[4]程鹏飞,魏增泉.抗血小板药物研究进展[J].世界中西医结合杂志,2012,7(7):639-642.
[5]吴小平,刘放.抗血小板聚集药物研究进展[J].西北药学杂志,2009,24(4):327-330.
[6]TORPHY TJ,UNDEM BJ.Phosphodiesterase inhibitors:new opportunities for the treatment of asthma[J].Thorax,1991,46(7):512-523.
[7]GIACHINI FR,LIMA VV,CARNEIRO FS,et al.Decreased c GMP level contributes to increased contraction in arteries from hypertensive rats:role of phosphodiesterase1[J].Hypertension,2011,57(3):655-663.
[8]陈昌亮,黄爽.磷酸二酯酶及其抑制剂的研究进展[J].中国药理学通报,2014,30(2):283-286.
[9]杨颖,蒋金法.新型抗血小板药物研究进展[J].外科研究与新技术,2014,3(4):263-266.
[10]崔炜,耿雪.新型抗栓药的临床应用[J].中国心血管杂志,2015,20(5):328-333.
[11]赵磊.双嘧达莫联合丹参酮ⅡA磺酸钠对心绞痛患者血流速度的影响[J].中国老年学,2012,32(20):4367-4368.
[12]DAVIDAI G,COTTON D,GORELICK P,et al.Dipyridamole-induced headache and lower recurrence risk in secondary prevention of ischaemicstroke:a post hoc analysis[J].Eur J Neurol,2014,21(10):1311-1317.
[13]徐伟,曹蘅.Ⅱb/Ⅲa受体抑制剂治疗急性冠脉综合征的最新研究进展[J].心脏杂志,2014,26(2):233-235.
[14]AHN SG,LEE SH,JI HL,et al.Efficacy of combination treatment with intracoronaryabciximab and aspirationthrombectomy on myocardialperfusion in patients with ST-segmentelevation myocardial infarction undergoing primary coronary stenting[J].Yonsei Med J,2014,55(3):606-616.
[15]陶军,刘磊,杨惜泉,等.阿昔单抗降低急性心肌梗死直接PTCA术缺血危险性的观察[J].中华老年心脑血管病杂志,2001,3(6):390-392.
[16]罗亚玮,陈方,潘昱,等.血小板糖蛋白Ⅱb/Ⅲa受体拮抗药替罗非班的抗血小板以外作用[J].中国药房,2015,26(2):278-281.
[17]CAVARRETTA E,CHIARIELLO GA,CONDORELLI G.Platelets,endothelium,and circulating microRNA-126 as a prognostic biomarker in cardiovascular diseases:per aspirin ad astra[J].Eur Heart J,2013,34(44):3400-3402.
[18]梁峰,胡大一,沈珠军,等.小剂量阿司匹林在心脑血管事件一级预防中的研究进展[J].中国医院用药评价与分析,2014,14(11):1044-1048.
[19]许璨.冠心病心绞痛患者经皮冠状动脉介入围手术期对阿司匹林和氯吡格雷抗血小板效应分析[J].心血管病防治知识,2015(8):67-68.
[20]MOUSA SA,JESKE WP,FAREED J.Antiplatelettherapyprasugrel:anovelplatelet ADP P2Y12 receptorantagonist[J].Clin Appl Thromb Hemost,2010,16(2):170-176.
[21]ELLIS KJ,STOUFFER GA,MCLEOD HL,et al.Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition:USFDA recommendations[J].Pharmacogenomics,2009,10(11):1799-1817.
[22]叶金朝.噻氯匹定的药理及临床应用[J].新药与临床,1990,9(5):291-292.
[23]李江,刘文娴,赵一楠,等.替格瑞洛在治疗氯吡格雷抵抗患者时血小板聚集率分析[J].中国全科医学,2014,17(19):2231-2234.
[24]何芸,王淑香,赵强,等.替格瑞洛与氯吡格雷用于急性冠状动脉综合征疗效及安全性比较的Meta分析[J].白求恩医学杂志,2015,13(4):354-356.
[25]张菁蕾.肝素抗凝血血浆用于急诊生化检验的效果分析[J].实用心脑肺血管病杂志,2013,21(11):104-105.
[26]王小东,刘学波.急性冠脉综合征新型抗凝药物研究进展[J].国际心血管病杂志,2015,42(1):6-9.
[27]高昉,储慧民.达比加群酯在心房颤动抗凝治疗方面的研究进展[J].临床荟萃,2015,30(11):1316-1320.
[28]姚璐,张薇,田国祥,等.达比加群酯应用于高龄老年非瓣膜性心房纤颤患者中的安全性评价[J].中国循证心血管医学杂志,2016,8(5):547-549.
[29]徐梅,韩强,杜金凤.一例口服华法林引起出血的病例分析[J].北方药学,2014,11(11):33-35.
[30]张清.新型Xa因子抑制剂——依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,37(2):151-155.
[31]王兵,刘颖,刘登科,等.直接Xa因子抑制剂贝曲沙班[J].现代药物与临床,2015,30(2):217-221.
[32]杨平.利伐沙班与华法林对非瓣膜性房颤预防血栓栓塞128例疗效观察[J].中国煤炭工业医学杂志,2015,18(1):14-16.
[33]苟冶然,龙小滨,白磊,等.RGD-重组葡激酶-人α微球蛋白融合蛋白原核表达、纯化及鉴定[J].基础医学与临床,2015,35(3):329-335.
[34]李淑娟,谢秀峰,陈凤英.重组人组织型纤溶酶原激酶衍生物静脉溶栓治疗急性心肌梗死的疗效观察[J].中西医结合心脑血管病杂志,2014,12(8):952-954.